Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Rees

Internal Medicine Raleigh, NC Medical Doctor

NPI 1144270737 CMS profile 6698

3200 Blue Ridge Rd, Ste 210, Raleigh, NC 27612

Open in the dashboard

General payments

$6,256

412 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Rees of Raleigh, NC is reported in the CMS Open Payments database as having received $6,256 across 412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184 10
2024 General $738 38
2023 General $862 57
2022 General $1,217 78
2021 General $1,218 79
2020 General $1,003 72
2019 General $1,035 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Rees
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Rees were reported at $184. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Rees Internal Medicine median Middle half National median
2019 $1,035 $159 $48–$570 $163
2020 $1,003 $119 $33–$402 $114
2021 $1,218 $135 $37–$521 $132
2022 $1,217 $141 $42–$496 $149
2023 $862 $149 $45–$519 $160
2024 $738 $154 $47–$537 $164
2025 $184 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,863 121 payments
  2. Amgen Inc. $646 54 payments
  3. Lilly USA, LLC $438 32 payments
  4. AstraZeneca Pharmaceuticals LP $358 26 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $345 22 payments
  6. AbbVie, Inc. $264 16 payments
  7. Abbott Laboratories $182 7 payments
  8. Sanofi-Aventis U.S. LLC $173 12 payments
  9. Merck Sharp & Dohme Corporation $147 11 payments
  10. Janssen Pharmaceuticals, Inc $146 10 payments
  11. Other $1,694 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,248 411 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,299 84 payments
  2. RYBELSUS $1,155 74 payments
  3. EVENITY $339 30 payments
  4. Prolia $335 30 payments
  5. FARXIGA $267 20 payments
  6. JARDIANCE Diabetes $260 16 payments
  7. JARDIANCE Diabetes $231 17 payments
  8. Wegovy $229 13 payments
  9. Repatha $229 20 payments
  10. Saxenda $184 13 payments
  11. Other $4,722 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

6,074

Median for Internal Medicine: 777

Drug cost

$761,107

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 119 $121,110
Eliquis Apixaban Brand 122 $102,625
Trulicity Dulaglutide Brand 94 $97,975
Mounjaro Tirzepatide Brand 79 $83,738
Rybelsus Semaglutide Brand 50 $74,459
Ozempic Semaglutide Brand 63 $58,068
Repatha Sureclick Evolocumab Brand 52 $54,744
Xarelto Rivaroxaban Brand 17 $25,147
Bydureon Bcise Exenatide Microspheres Brand 14 $15,435
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 12 $11,532

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$62,031

Of which drugs: $17,484

Medicare patients

191

Average age 75

Services billed

1,715

82 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 34%
Ischemic heart disease 32%
Diabetes 23%
Atrial fibrillation 22%
Cancer 21%
Osteoporosis 17%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 26 26 $2,127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $140
$140 — —
RYBELSUS
  • Novo Nordisk Inc $103
$103 50 —
Ozempic
  • Novo Nordisk Inc $103
$103 63 —
Veozah
  • Astellas Pharma US Inc $75
$75 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $31
  • Lilly USA, LLC $22
$53 119 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record